|
| Issue Date | Title | Author(s) |
| 2018 | After successful hepatitis C virus antiviral therapy: It looks that normal alanine aminotransferase level is not the normal | El Kassas, M.; Alboraie, M.; Mostafa, A. ; Ezzat, R.; El Tahan, A.; Afify, S.; Sweedy, A.; Kabbash, I.; Esmat, G. |
| 2014 | Effectiveness and cost-effectiveness of immediate versus delayed treatment of hepatitis C virus-infected patients in a country with limited resources: The case of Egypt | Obach, D.; Deuffic-Burban, S.; Esmat, G.; Anwar, W.A. ; Dewedar, S.; Canva, V.; Cousien, A.; Doss, W.; Mostafa, A. ; Pol, S.; Buti, M.; Siebert, U.; Fontanet, A.; Mohamed, M.K. ; Yazdanpanah, Y. |
| 2016 | Excess mortality rate associated with hepatitis C virus infection: A community-based cohort study in rural Egypt | Aya Mostafa Kamal ; Shimakawa, Y.; Medhat A. ; Mikhail, N.N.; Chesnais, C.B.; Arafa, N.; Bakr, I.; El Hoseiny, M.; El-Daly, M.; Esmat, G.; Abdel-Hamid, M.Y. ; Mohamed, M.K. ; Fontanet, A. |
| 2010 | Hepatitis C infection and clearance: Impact on atherosclerosis and cardiometabolic risk factors | Mostafa, A. ; Mohamed, M.K. ; Said, M.; Hasan, A.; Fontanet, A.; Godsland, I.; Coady, E.; Esmat, G.; El-Hoseiny, M.; Abdul-Hamid, M.; Hughes, A.; Chaturvedi, N. |
| 2015 | How to Optimize Hepatitis C Virus Treatment Impact on Life Years Saved in Resource-Constrained Countries | Obach, D.; Yazdanpanah, Y.; Esmat, G.; Avihingsanon, A.; Dewedar, S.; Durier, N.; Attia, A.; Anwar, W.A. ; Cousien, A.; Tangkijvanich, P.; Eholié, S.P.; Doss, W.; Mostafa, A. ; Fontanet, A.; Mohamed, M.K. ; Deuffic-Burban, S. |
| 2014 | Is expert opinion reliable when estimating transition probabilities? the case of HCV-related cirrhosis in Egypt | Cousien, A.; Obach, D.; Deuffic-Burban, S.; Mostafa, A. ; Esmat, G.; Canva, V.; El Kassas, M.; El-Sayed, M.; Anwar, W.A. ; Fontanet, A.; Mohamed, M.K. ; Yazdanpanah, Y. |
